FEMARA® (letrozole) is taken as a once-daily tablet at the time of day your patients choose1
In adult and elderly patients, the recommended daily dose of FEMARA® is one 2.5-mg tablet taken without regard to meals.1 FEMARA® can be taken with cimetidine, warfarin, and other commonly prescribed drugs.1
No dose adjustment is required for elderly patients, patients with mild to moderate hepatic impairment, or patients with renal impairment (creatinine clearance >30 mL/min).1 FEMARA® is not recommended for use in children.1
In the initial adjuvant setting1
Treatment with FEMARA® (letrozole) should continue for 5 years or until tumor relapse occurs.
Following adjuvant tamoxifen1
In the extended adjuvant setting, clinical experience is available for 4 years (median duration of treatment).
For advanced or metastatic disease1
In patients with advanced or metastatic disease, treatment with FEMARA® should continue until tumor progression is evident.
For proven therapy with convenient and flexible once-daily dosing, turn to FEMARA® (letrozole).
To read about the unique efficacy profile of FEMARA® in the initial adjuvant setting, click here.
For general information about FEMARA®, see the Summary of Product Characteristics, click here.
FEMARA® is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
FEMARA® is also indicated for:
Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-estrogens.
Click here for Important Safety Information for FEMARA®.
Reference: 1. FEMARA® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009.